In the last trading session, 14.01 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.85. With the company’s per share price at $4.51 changed hands at -$0.05 or -1.10% during last session, the market valuation stood at $1.83B. RXRX’s last price was a discount, traded about -174.06% off its 52-week high of $12.36. The share price had its 52-week low at $3.79, which suggests the last value was 15.96% up since then.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.43. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in red as seen at the end of in last trading. With action -2.80%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -33.28%, with the 5-day performance at -2.80% in the red. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -18.00% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 24.83% from its current market value. According to analyst projections, RXRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -33.04% plunge from its current level, while the stock would need to soar -33.04% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.28%. The 2025 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 15.09%, but the outlook for the next 5-year period is at 19.85% per year.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF. With 18.65 shares estimated at $84.12 million under it, the former controlled 4.67% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 2.95% of the shares, roughly 11.78 shares worth around $53.12 million.
